Article Text
Statistics from Altmetric.com
Antitumour necrosis factor α drugs dramatically changed the prognosis of juvenile idiopathic arthritis (JIA), the most common chronic rheumatic disease in childhood. Promising results from janus kinase inhibitors (JAKi), small molecules orally administered that inhibit specific receptor of the JAK family, are emerging. Tofacitinib, a non-selective JAKi, has shown an excellent efficacy in a recent randomised controlled trial(RCT) for polyarticular JIA.1
Baricitinib, a selective JAK 1 and JAK 2 inhibitor, resulted superior to placebo and adalimumab (ADA) in treating rheumatoid arthritis.2 Data are, however, scarce in JIA, and results from ongoing RCTs are still pending(NCT03773978, NCT03773965, NCT04088409).
We, here, report four patients with polyarticular JIA children, fulfilling ILAR criteria, treated with baricitinib (4 mg) (table 1). All patients received an extensive infectious workup before drug starting.
- In this window
- In a new window
Patient 1 is a 13-year-old Caucasian female with psoriatic arthritis, who previously obtained remission combining methotrexate (MTX) and ADA as methotrexate …
Footnotes
Handling editor Josef S Smolen
Contributors IM and TO wrote the first draft of the manuscript. IM and GS conceptualised the study and review the final version of the manuscript. IP, EM and MVM revised the final draft of the manuscript. All the authours followed the patients during their follow-up.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
Provenance and peer review Not commissioned; externally peer reviewed.